Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.
- The company said it will fund the repurchase with cash in hand.
- The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.
- During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data.
Shares of Arbutus Biopharma Corporation (ABUS) surged over 10% in pre-market trading on Friday after the firm announced its intent to repurchase up to $230 million of its common shares.
Arbutus Biopharma said it will repurchase the common shares at a purchase price of not less than $5 per share and not more than $5.75 per share, in cash, less any applicable withholding taxes and without interest.
The company said it will fund the repurchase with cash in hand. The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.
If Friday’s pre-market level holds, the stock will hit its July highs.
International Lawsuits
Last month, the company, along with its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their innovative LNP technology against Pfizer Inc., BioNTech SE and certain of their affiliates.
“We, alongside our exclusive licensee Genevant, will continue to vigorously enforce our rights against infringers, including Pfizer and BioNTech,” said Arbutus Biopharma CEO Lindsay Androski.
“Our March 2026 settlement with Moderna, and the July 2026 initial payment under that settlement, were critical milestones in establishing for the world what most of the scientific community already knew: Arbutus’ lipid nanoparticle technology inventions opened the doors to an entirely new world of therapeutic treatments using nucleic acids,” she added.
ABUS’ Q2 At A Glance
During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data. The firm reported a loss of $0.03 per share compared to an estimated $0.02.
Arbutus Biopharma ended the quarter with cash, cash equivalents, and investments in marketable securities of $92.6 million.
What Retail Thinks About ABUS
On Stocktwits, retail sentiment continued to trend in the ‘extremely bullish’ territory amid high message volume.
Stocktwits users expect the stock to rise to at least $6.5. It is currently trading close to $5.3, according to the pre-market rate.
View this Stocktwits post
View this Stocktwits post
The stock has gained nearly 33% in the last year.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<